Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel–Lindau Disease

Targeting β2-Adrenergic Receptors Shows Therapeutical Benefits in Clear Cell Renal Cell Carcinoma from Von Hippel–Lindau Disease

Von<b> </b>Hippel–Lindau (VHL), is a rare autosomal dominant inherited cancer in which the lack of VHL protein triggers the development of multisystemic tumors such us retinal hemangioblastomas (HB), CNS-HB, and clear cell renal cell carcinoma (ccRCC). ccRCC ranks third in terms of incid...

Full description

Bibliographic Details
Main Authors: Virginia Albiñana, Eunate Gallardo-Vara, Isabel de Rojas-P, Lucia Recio-Poveda, Tania Aguado, Ana Canto-Cano, Daniel T. Aguirre, Marcelo M. Serra, Pilar González-Peramato, Luis Martínez-Piñeiro, Angel M. Cuesta, Luisa Maria Botella
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Journal of Clinical Medicine
Subjects:
β-adrenergic receptor antagonist
ICI-118,551
propranolol
HIF
ccRCC
VHL
Online Access:https://www.mdpi.com/2077-0383/9/9/2740

Internet

https://www.mdpi.com/2077-0383/9/9/2740

Similar Items